Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.52 |
| ▸ | CSF1R | P07333 | 3/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172904 | 0.88 | PDGFRA (0.64) | METFLT3PDGFRBCSF1RFLT4 | |
| SCHEMBL2174184 | 0.88 | PDGFRB (0.55) | METAXLFLT3PDGFRBCSF1R | |
| SCHEMBL4504727 | 0.87 | MET (0.54) | METAXLFLT3PDGFRBCSF1R | |
| SCHEMBL14967576 | 0.83 | MET (0.60) | METAXLFLT3PDGFRBCSF1R | |
| SCHEMBL19957407 | 0.82 | MET (0.52) | METFLT3PDGFRBCSF1RFLT4 | |
| SCHEMBL2176424 | 0.82 | AXL (0.62) | METAXLFLT3PDGFRBCSF1R | |
| SCHEMBL2173091 | 0.82 | KDR (0.64) | METAXLFLT3PDGFRBFLT4 | |
| SCHEMBL2174778 | 0.82 | CSF1R (0.60) | METAXLFLT3PDGFRBCSF1R | |
| SCHEMBL2173639 | 0.82 | MET (0.62) | METAXLFLT3PDGFRBCSF1R | |
| SCHEMBL2174008 | 0.81 | MET (0.51) | METAXLFLT3PDGFRBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | MET 3334/4885AXL 3664/4885FLT3 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.